抗凋亡基因Bfl-1在前列腺癌中的表达及作用

The Expression and Function of Anti-apoptotic Bfl-1 in Prostate Cancer

目的检测Bcl2相关蛋白A1(Bfl-1)mRNA在前列腺癌细胞株、前列腺癌组织及良性前列腺增生组织中的表达,观测阻断Bfl-1表达对前列腺癌细胞的影响,探讨Bfl-1在前列腺癌发生发展中的作用。方法采用RT-PCR、实时荧光定量PCR(Q-PCR)、cDNA探针原位杂交(ISH)等技术检测Bfl-1mRNA在前列腺癌组织、细胞株和良性前列腺增生组织的表达水平;结合临床资料分析Bfl-1的表达与临床病理指标的关系;利用反义寡核苷酸干预前列腺癌细胞株,RT-PCR检测Bfl-1表达,MTT法检测细胞的存活,倒置显微镜下观察前列腺癌细胞的形态变化。结果 RT-PCR、Q-PCR结果显示Bfl-1mRNA在激素非依赖性前列腺癌细胞株PC-3和DU145中高表达,在激素依赖性前列腺癌细胞株LNCaP中未见表达,表达差异有统计学意义(P<0.05);原位杂交结果显示Bfl-1mRNA在前列腺癌组织中高表达,而在良性前列腺增生组织中未见表达,表达差异有统计学意义(P<0.05);有转移、分期高的前列腺癌病例的Bfl-1mRNA表达水平高于无转移、分期低的病例(P<0.05);Bfl-1反义寡核苷酸转染PC-3和DU145细胞后,Bfl-1表达下调,细胞生长受到抑制(P<0.05),细胞脱落、碎裂形成大小不一的细胞团块。结论激素非依赖性前列腺癌细胞的生长与Bfl-1过表达有关;干预Bfl-1表达可能成为晚期前列腺癌治疗的新策略。

Objective To determine the expression of Bcl2 related protein A1 （Bfl-1） mRNA in prostate cancer cell lines and tissues, and to explore the functions of Bfl-1 in prostate adenocarcinoma. Methods RT-PCR, real-time quantitative PCR（Q-PCR）and in situ hybridization （ISH） were used to detect the expression of Bfl-1 mRNA in prostate cancer cell lines, tissues and benign prostate hyperplasia （BPH） tissue samples. The relationship between Bfl-1 expression and clinicopathological parameters was analyzed. Antisense oligonucleotides （ASONs） were used to interfere the expression of Bfl-1 and its effects on prostate cancer cells. MTT was used to detect the survival, morphologic changes of prostate cancer cells was observed by inverted microscope. Results Bfl-1 mRNA, detected by RT-PCR, Q-PCR and ISH, was overexpressed in the androgen-independent prostate cancer cell lines PC-3 and DU145, but not detectable in the androgen-dependent prostate cancer cell line LNCaP and BPH tissue samples （P^0.05）. Significantly higher Bfl-1 mRNA levels were observed in higher stage and metastatic prostate cancer cases than those without metastasis or of low stage. ASONs targeting Bfl-1 significantly inhibited androgen- independent prostate cancer cell growth （P^0.05）, cell was rounding off or fragmentation. Conclusion Bfl-1 is involved in maintaining the hormone-independent prostate cancer cell growth. Bfl-1 may become a new therapeutic target in advanced prostate cancer.